If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
ACADEMIA
Most Mild COVID-19 Patients Recovered on Avigan, but Careful Interpretations Needed for Single-Arm Study: Interim Report
Most mildly ill patients with COVID-19 recovered on the antiviral agent Avigan (favipiravir) in an observational clinical study in Japan, but the results should be interpreted carefully given that there is no control group set and many mild cases tend…
To read the full story
Related Article
- Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
- Avigan’s COVID-19 Use Up for PAFSC Review on December 21
December 17, 2020
- Avigan to Come Up for PAFSC Review This Month
December 16, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
- Fujifilm’s Avigan COVID-19 Data Won’t Be Fully Ready until 1 Month from Now
August 21, 2020
- Fujifilm-Sponsored Avigan Trial to Complete Enrollment on Aug. 16
August 12, 2020
- Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
- Fujifilm Inks Global Avigan Deal with Dr. Reddy’s, Global Response Aid
July 2, 2020
- Fujifilm’s Avigan COVID-19 Trial Might Continue into July
June 9, 2020
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
ACADEMIA
- Use Oral Dexamethasone for COVID-19 Patients Requiring Oxygen: Scientific Societies
September 10, 2021
- Oita University to Begin PI Study for Replicon RNA Vaccine in October
September 10, 2021
- Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
September 9, 2021
- Darzquro Expected to Treat 900 AL Amyloidosis Patients in Japan Annually: Specialist
September 6, 2021
- 1st COVID-19 Delta Variant Mutation Found in Japan: TMDU
August 31, 2021
Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…